NASDAQ:CARA Cara Therapeutics (CARA) Stock Forecast, Price & News $1.67 -0.05 (-2.91%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.66▼$1.7350-Day Range$1.67▼$3.3352-Week Range$1.66▼$12.81Volume561,633 shsAverage Volume873,852 shsMarket Capitalization$90.31 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Cara Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside918.0% Upside$17.00 Price TargetShort InterestHealthy3.45% of Float Sold ShortDividend StrengthN/ASustainability-1.39Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$32,443 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.93) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsMedical Sector114th out of 967 stocksPharmaceutical Preparations Industry33rd out of 443 stocks 3.3 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Cara Therapeutics has a forecasted upside of 918.0% from its current price of $1.67.Amount of Analyst CoverageCara Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.45% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently decreased by 40.84%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.Environmental SustainabilityThe Environmental Impact score for Cara Therapeutics is -1.39. Previous Next 1.3 News and Social Media Coverage News SentimentCara Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cara Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for CARA on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,443.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions68.04% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($1.93) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cara Therapeutics (NASDAQ:CARA) StockCara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.Read More CARA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARA Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Share Price Passes Below Two Hundred Day Moving Average of $3.66September 14, 2023 | finance.yahoo.comCompanies Like Cara Therapeutics (NASDAQ:CARA) Could Be Quite RiskySeptember 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 10, 2023 | finance.yahoo.comCara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | msn.comPiper Sandler Maintains Cara Therapeutics (CARA) Overweight RecommendationAugust 8, 2023 | markets.businessinsider.com6 Analysts Have This to Say About Cara TherapeuticsAugust 8, 2023 | finance.yahoo.comQ2 2023 Cara Therapeutics Inc Earnings CallAugust 8, 2023 | finance.yahoo.comCara Therapeutics Reports Second Quarter 2023 Financial ResultsSeptember 23, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 3, 2023 | finance.yahoo.comCara Therapeutics Appoints Helen M. Boudreau to Board of DirectorsJuly 24, 2023 | finance.yahoo.comCara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023June 28, 2023 | msn.comStifel Reiterates Cara Therapeutics (CARA) Buy RecommendationJune 27, 2023 | msn.comJefferies Reiterates Cara Therapeutics (CARA) Buy RecommendationJune 27, 2023 | benzinga.comStifel Reiterates Buy on Cara Therapeutics, Maintains $28 Price TargetJune 27, 2023 | msn.comJefferies says CMS extension for CARA dialysis drug should "unlock stock"June 27, 2023 | benzinga.comJefferies Reiterates Buy on Cara Therapeutics, Maintains $18 Price TargetJune 22, 2023 | msn.comBullish Thursday For Marijuana Stocks - Aurora Cannabis, Cara Therapeutics Among Top GainersJune 14, 2023 | finance.yahoo.comThe past five years for Cara Therapeutics (NASDAQ:CARA) investors has not been profitableJune 6, 2023 | marketwatch.comSeveral Stocks Touch 52-Week Lows After S&P Indices MovesMay 29, 2023 | benzinga.comPain Relief Therapeutics Market to Grow Significantly by 2029- Brandessence Market ResearchMay 25, 2023 | fool.comCara Therapeutics (NASDAQ: CARA)May 25, 2023 | finance.yahoo.comCara Therapeutics, Inc.'s (NASDAQ:CARA) P/S Is On The MarkMay 18, 2023 | msn.comUK drug pricing watchdog backs use of Cara, Vifor's Kapruvia in NHSMay 18, 2023 | finance.yahoo.comKapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritusMay 16, 2023 | msn.comB of A Securities Maintains Cara Therapeutics (CARA) Underperform RecommendationMay 16, 2023 | msn.comHC Wainwright & Co. Maintains Cara Therapeutics (CARA) Buy RecommendationMay 16, 2023 | finance.yahoo.comQ1 2023 Cara Therapeutics Inc Earnings CallSee More Headlines Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARA Company Calendar Last Earnings8/07/2023Today9/23/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees106Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+918.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-85,470,000.00 Net Margins-410.95% Pretax Margin-410.95% Return on Equity-75.82% Return on Assets-65.36% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.77 Sales & Book Value Annual Sales$27.17 million Price / Sales3.32 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book0.57Miscellaneous Outstanding Shares54,078,000Free Float51,807,000Market Cap$90.31 million OptionableOptionable Beta0.87 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Christopher A. Posner (Age 53)Pres, CEO & Director Comp: $1.2MMr. Ryan D. Maynard (Age 54)Chief Financial Officer Comp: $511.7kDr. Joana Goncalves M.D. (Age 49)Chief Medical Officer Comp: $747.25kDr. Derek T. Chalmers D.Sc. (Age 59)Ph.D., Co-Founder & Sr. Advisor Dr. Frédérique Menzaghi (Age 57)Chief Scientific Officer and Sr. VP of R&D Dr. Iris Francesconi Ph.D.Chief Strategy Officer & Head of Investor RelationsMr. Scott M. Terrillion (Age 60)Chief Compliance Officer, Gen. Counsel & Corp. Sec. Mr. Eric VandalSr. VP of CommercialMs. Beth Weinberg R.Ph.Sr. VP of Regulatory Affairs & QAMr. Matthew MurphyMang. of Investor RelationsMore ExecutivesKey CompetitorsMediciNovaNASDAQ:MNOVBioVieNASDAQ:BIVILumiraDxNASDAQ:LMDXCue BiopharmaNASDAQ:CUEMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsBarclays PLCSold 19,088 shares on 9/21/2023Ownership: 0.017%Jag Capital Management LLCBought 11,235 shares on 9/7/2023Ownership: 0.021%California State Teachers Retirement SystemSold 41,221 shares on 8/21/2023Ownership: 0.029%Wells Fargo & Company MNBought 4,838 shares on 8/15/2023Ownership: 0.083%Citadel Advisors LLCSold 3,200 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CARA Stock - Frequently Asked Questions Should I buy or sell Cara Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CARA shares. View CARA analyst ratings or view top-rated stocks. What is Cara Therapeutics' stock price forecast for 2023? 6 analysts have issued 1-year price targets for Cara Therapeutics' stock. Their CARA share price forecasts range from $4.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 918.0% from the stock's current price. View analysts price targets for CARA or view top-rated stocks among Wall Street analysts. How have CARA shares performed in 2023? Cara Therapeutics' stock was trading at $10.74 at the beginning of the year. Since then, CARA stock has decreased by 84.5% and is now trading at $1.67. View the best growth stocks for 2023 here. Are investors shorting Cara Therapeutics? Cara Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 1,550,000 shares, a decrease of 40.8% from the August 15th total of 2,620,000 shares. Based on an average trading volume of 1,300,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 3.5% of the company's shares are short sold. View Cara Therapeutics' Short Interest. When is Cara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our CARA earnings forecast. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) posted its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.02. The biopharmaceutical company earned $6.93 million during the quarter, compared to analysts' expectations of $6.49 million. Cara Therapeutics had a negative net margin of 410.95% and a negative trailing twelve-month return on equity of 75.82%. What ETF holds Cara Therapeutics' stock ? Amplify Seymour Cannabis ETF holds 161,542 shares of CARA stock, representing 1.93% of its portfolio. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY). What is Cara Therapeutics' stock symbol? Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA." Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.85%), Clearbridge Investments LLC (1.85%), Bain Capital Life Sciences Investors LLC (1.73%), Geode Capital Management LLC (1.73%), State Street Corp (1.70%) and Pinnacle Associates Ltd. (1.25%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly. View institutional ownership trends. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cara Therapeutics' stock price today? One share of CARA stock can currently be purchased for approximately $1.67. How much money does Cara Therapeutics make? Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $90.31 million and generates $27.17 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. How many employees does Cara Therapeutics have? The company employs 106 workers across the globe. How can I contact Cara Therapeutics? Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510. This page (NASDAQ:CARA) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.